This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: November 6, 2013
Last updated: February 15, 2017
Last verified: February 2017
To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.

Condition Intervention Phase
Restless Legs Syndrome (RLS) Drug: Gabapentin enacarbil Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post-marketing Clinical Study of Gabapentin Enacarbil ―Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment―

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change in International Restless Leg Syndrome (IRLS) rating scale score [ Time Frame: Baseline and at 4 week of the treatment (or at discontinuation) ]

Secondary Outcome Measures:
  • Change in Investigator-rated clinical global impression (ICGI) score [ Time Frame: Baseline and at 4 week of the treatment (or at discontinuation) ]
  • Change in Patient-related clinical global impression (PCGI) score [ Time Frame: Baseline and at 4 week of the treatment (or at discontinuation) ]
    Baseline and at 4 week of the treatment (or at discontinuation)

  • Safety assessed by the incidence of adverse events, vital signs, labo-tests, body weight and Epworth sleepiness scale [ Time Frame: Up to 5 weeks ]
  • Plasma gabapentin concentration [ Time Frame: Up to 5 weeks ]

Enrollment: 19
Study Start Date: May 2013
Study Completion Date: May 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment group
Drug: Gabapentin enacarbil

Detailed Description:
This study is a multicenter, non-blinded, non-comparative study. Patients who meet the eligible criteria will undergo one week observation period followed by four week treatment period. In treatment period, patients will receive gabapentin enacarbil orally one daily after dinner. After the four-week treatment period with gabapentin enacarbil, a one-week post-observation period will be undertaken.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have been diagnosed with restless legs syndrome (RLS) according to the international RLS Study Group Diagnostic Criteria
  • Patients whose score is 15 or greater on the International RLS (IRLS) Rating Scale on the first day of the pre-observation period.
  • Patients whose creatinine clearance level at the first day of pre-observation period is ≥30 mL/min to <60mL/min estimated by Cockcroft-Gaul t equation
  • Patients who provide written consent

Exclusion Criteria:

  • Patients with sleep disorder such as sleep apnea syndrome, which affects the RLS evaluation
  • Patients with history of augmentation and treatment rebound of RLS symptoms when using dopamine agonis
  • Patients with neuropathy and movement disorder (diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesia, rheumatoid arthritis etc)
  • Patients with uncontrolled diabetes [HbA1c>7.5% (NGSP value), in the past six months], iron deficiency anemia, or drug administration of hypnotic sedatives.
  • Patients who attempted suicide within six months prior to the consent obtained, or who have been diagnosed as a suicide risk by investigator or sub-investigator
  • Patients with moderate or severe depression
  • Patients with alcohol dependence or drug intoxication or who have a history of abuse or drug dependence in the past one year
  • Patients whose job is shift work, professional driver, or engaging in hazardous activities such as operating machinery
  • Patients with history of hypersensitivity to gabapentin
  • Patients who have experience to participate in other post-marketing clinical studies or clinical trials within 12 weeks prior to the start of pre-observation
  • Others: patients who are concluded to be ineligible by an investigator or sub-investigator as ineligible
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01981941

Chubu, Japan
Chugoku, Japan
Kansai, Japan
Kanto, Japan
Kyushu, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Principal Investigator: Medical Director Astellas Pharma Inc
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT01981941     History of Changes
Other Study ID Numbers: 8825-CL-0103
Study First Received: November 6, 2013
Last Updated: February 15, 2017

Keywords provided by Astellas Pharma Inc:
Restless legs syndrome (RLS)

Additional relevant MeSH terms:
Psychomotor Agitation
Restless Legs Syndrome
Renal Insufficiency
Pathologic Processes
Kidney Diseases
Urologic Diseases
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
gamma-Aminobutyric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators processed this record on September 21, 2017